Skip to main content
Infilbray™ (venglustat) logo
A young boy playing a keyboard overlayed with purple light
A young boy playing a keyboard overlayed with purple light

Infilbray™ (venglustat) pivotal clinical trial data: Demonstrated neurologic improvement1

Jump to:

Infilbray showed superior neurologic improvement compared with imiglucerase, as assessed through the O’Brien OLS global test evaluating multiple endpoints in motor and cognitive function, in patients 12 years and older with Gaucher disease type 3.1,a

P value=0.0137.1 

aAs measured by 4-item SARA and RBANS at Week 52.1 

Infilbray was studied in a pivotal, phase 3 trial1

A randomized, double-blind, double-dummy, active-controlled, multicenter trial1

Schematic of trial design that shows inclusion criteria, randomized treatment arms, and study endpoint

Patients were excluded from this study if they had progressive myoclonic epilepsy or severe depression.2

Median length of ERT treatment prior to enrollment was 14 years, ranging from 3 to 26 years.1

aPatients were stratified by age group (12 to 17 years; 18 years and older).1

bFor ≥3 years.1 
cPatients must have had gaze palsy and some sign of ataxia, defined as a modified SARA score of 1 or above, to be included in the study.2 
dFour-item SARA score evaluated neurologic motor function across 4 domains, including: gait, stance, sitting, and speech disturbance. RBANS assessed cognitive function across 5 domains, including: immediate memory, visuospatial/constructional abilities, language, attention, and delayed memory.1

Infilbray showed superior neurologic improvement compared with imiglucerase in patients ≥12 years of age1

Infilbray demonstrated statistical superiority versus imiglucerase based on the O'Brien OLS global test of RBANS and 4-item SARA scores at Week 521

O'Brien OLS global test, P value=0.01371

Cognitive score (RBANS): An improvement with Infilbray was observed1 

Infilbray baseline mean (SD): 78.57 (18.28) 

Imiglucerase baseline mean (SD): 68.36 (20.87)

Line icon of a brain

LS mean changes at Week 52

Bar graph showing the difference in cognitive score on Infilbray™ (venglustat) when compared to imiglucerase

Infilbray Week 52 mean (SD): 80.55 (19.24)

Imiglucerase Week 52 mean (SD): 66.14 (16.79)

Motor function (4-item SARA): An improvement with Infilbray was observed1

Infilbray baseline mean (SD): 2.19 (1.47)
  
Imiglucerase baseline mean (SD): 3.18 (2.38)

Line icon of a person walking

LS mean changes at Week 52

Bar graph showing motor function score of Infilbray™ (venglustat) compared to imiglucerase

Infilbray Week 52 mean (SD): 1.71 (1.52)

Imiglucerase Week 52 mean (SD): 2.81 (2.32)

aHigher RBANS scores and lower 4-item SARA scores indicate improvement from baseline in cognitive and neurologic motor function, respectively.1 
 Statistical significance based on a global test that weighted both scores; RBANS and 4-item SARA were not evaluated individually.1

Understanding RBANS and SARA scores

Change in cognitive and motor function from baseline to Week 52 was evaluated1,2

Change in 5 RBANS domain scores from baseline to Week 522

Bar graph showing the change in scores in RBANS domains in patients on Infilbray™ (venglustat) vs. imiglucerase

Individual components of RBANS were not prespecified and are descriptive in nature. Data should be interpreted with caution.

Increase = improvement1

A positive change in total RBANS score represents improved cognitive function.

Understanding RBANS scores

Change in 4-item SARA scores from baseline to Week 521,2

Bar graph showing the change in scores in 4-item SARA domains in patients on Infilbray™ (venglustat) vs imiglucerase

Individual components of 4-item SARA were not prespecified and are descriptive in nature. Data should be interpreted with caution.



Sitting cannot be displayed because only 4 patients participated with non-zero change.2 

Decrease = improvement1 

A negative change in total 4-item SARA represents improved motor function.

aRepresents no change.

Understanding SARA scores

Understanding the primary endpoint of the pivotal trial1

Total RBANS score

Schematic of a color gradient measuring increasing impairment, indicating that a lower score represents a greater level of cognitive impairment

Total 4-item SARA score

Schematic of a color gradient measuring increasing ataxia, indicating that a higher score represents increasing ataxia

Definitions: ERT=enzyme replacement therapy; LS=least squares; OLS=ordinary least squares; Q2W=every two weeks; RBANS=Repeatable Battery for the Assessment of Neuropsychological Status; SARA=Scale for the Assessment and Rating of Ataxia; SD=standard deviation.

Relevant pages to view:

Indication

INFILBRAY (venglustat) is indicated for the treatment of neurological manifestations of Type 3 Gaucher disease (GD3) in patients weighing at least 15 kg. 

Important Safety Information

Warnings and Precautions:
Suicidal Ideation and Behavior:

Suicidal ideation and behavior have been reported in patients with GD3 receiving INFILBRAY and in unapproved populations receiving another formulation of venglustat, both with and without a history of psychiatric disorders. Assess patients' underlying risk of psychiatric disorders prior to initiation and monitor for depressive symptoms or suicidal thoughts during treatment. Use caution when prescribing to patients with a history of psychiatric disorders. Inform patients or caregivers of the potential for behavioral and mood changes and to seek medical attention for manifestations of suicidal ideation and behavior, new onset or worsening depression, or other mood changes. Consider changing the therapeutic regimen, including possibly discontinuing INFILBRAY, if such events occur.

Lens Opacification in Pediatric Patients:

Lens opacification may occur in pediatric patients treated with INFILBRAY. In pediatric patients, perform ophthalmological assessment prior to initiation and annually during treatment. Advise pediatric patients and caregivers to report any visual disturbances during treatment.

Embryofetal Toxicity:

Based on animal studies, INFILBRAY may cause fetal harm when administered to a pregnant woman. Prior to initiation, verify pregnancy status in females of reproductive potential and advise them of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 11 days after the last dose.

Adverse Reactions:
The most common adverse reactions reported in ≥10% of INFILBRAY-treated GD3 patients aged ≥12 years were diarrhea, splenomegaly, nausea, depression, gastroenteritis, and vomiting.


Drug Interactions:
Strong CYP3A Inhibitors: Avoid concomitant use with INFILBRAY. Strong CYP3A inhibitors increase venglustat exposure, which may increase the risk of adverse reactions. If concomitant use is unavoidable, reduce INFILBRAY dosage.

Strong or Moderate CYP3A Inducers: Avoid concomitant use with INFILBRAY. Strong or moderate CYP3A inducers decrease venglustat exposure, which may result in decreased efficacy. If concomitant use is unavoidable, monitor for reduced effectiveness.

Please see Full Prescribing Information for INFILBRAY.

Indication

Important Safety Information

References: 1. Infilbray (venglustat). Prescribing information. Genzyme Corporation, Cambridge, MA. 2. Mistry P et al. Poster presented at: WORLDSymposium; February 2-6, 2026; San Diego, CA. 

©2026 Sanofi. All rights reserved. All trademarks mentioned are the property of the Sanofi group. MAT-US-2608186-v1.0-11/2026. Last updated: November 2026.